The divide/Eight fault lines

Medicine as it is run, against medicine as it could be.

Not a fantasy of a different science. The same evidence, the same molecules, the same clinicians — with the record open instead of held. Below, each place where the two versions part company, and what keeps the second one out of reach.

Today's medicine is not short of evidence. It is short of access to it — and the shortage is not an accident of science. It is administered.

01The comparison

Where the present system and the available one divide.

Each row states what actually happens, what the published record already allows, and the specific obstacle in between. No row requires a hidden room; each requires only an incentive left in place.

01

Publication of results

As it operates now

A study that finds nothing is treated as a failed study. Results go unpublished, and the literature ends up holding the flattering half of the record while the other half stays in a drawer.

Where the record already points

Every registered trial's result is published within a fixed period, null results included, so that what a physician reads is the whole record and not a selection of it.

Obstacle · The party that paid for the study also decides whether anyone sees it.

02

Access to the underlying data

As it operates now

Patient-level data sits with the sponsor and with the regulator. A researcher who asks to re-analyse it is refused, and the refusal is normal enough that it is rarely reported.

Where the record already points

Market authorisation is conditional on anonymised data being open to independent re-analysis, so a claim can be checked instead of accepted.

Obstacle · Data is treated as private commercial property rather than as a public trust.

03

Molecules nobody owns

As it operates now

A cheap, off-patent molecule has no owner with a reason to fund the trial that would license it. The question goes unstudied for decades, and being unstudied is then mistaken for being disproven.

Where the record already points

Public money funds the trials that private money will not, priced to the public benefit. An unstudied question becomes a funded line item, not a permanent blind spot.

Obstacle · Clinical research follows exclusivity, not need.

04

Post-market signals

As it operates now

Harm reporting is passive and voluntary. A signal can be received, logged, absorbed and never resolved, and no one has to decide anything by a date.

Where the record already points

Active surveillance, mandatory reporting, published signal counts, and a decision deadline for every signal raised — including the decision not to act, which must be written down.

Obstacle · The body that assesses the product is the body that approved it.

05

A doctor's licence

As it operates now

A clinician who reads the whole record and treats inside it can be investigated for departing from consensus. The complaint, not the outcome, becomes the punishment.

Where the record already points

A licence measures competence, not conformity. Treatment supported by the evidence is a defence in any disciplinary proceeding, and the reasoning is published.

Obstacle · Consensus is used as the standard of care, and deviation from it as misconduct.

06

Informed consent

As it operates now

Consent is taken against a narrowed summary in which uncertainty is described as settled. The patient is asked to agree to a conclusion, not to weigh a question.

Where the record already points

Consent states what is known, what is not known, and what the competing evidence suggests — in the patient's own reading level, with the alternatives named.

Obstacle · The institution that made the claim also writes the disclosure.

07

The cost of not asking

As it operates now

An unanswered question is not a line in any budget, so no institution is accountable for it. Harm that follows from a question never asked belongs to nobody.

Where the record already points

A public register of unanswered questions, each with an owner and a date. Failure to ask becomes measurable, and measurable things can be answered to.

Obstacle · Institutions are measured on what they delivered, never on what they failed to investigate.

08

Who watches the regulator

As it operates now

The regulator is funded in part by the industry it regulates, and staffed by people who move between the two. The arrangement is not hidden; it is simply not treated as a conflict.

Where the record already points

Independent funding, published conflicts for every decision-maker, and a cooling-off period before and after public service.

Obstacle · The revolving door is not a scandal. It is a career path.

02Summary

The clear picture, stated without decoration.

The picture, in short

The gap is not a missing molecule. It is a question of custody: who holds the record, who may read it, and who decides what counts as settled. Every row above is an answer to that question, and in each one the same party holds the evidence, writes the summary and judges the result.

None of this requires a conspiracy in a locked room. It requires only incentives left in place long enough to become procedure — a publication system that rewards novelty, a regulator funded by the regulated, a licence that punishes dissent, a consent form that sells certainty. Procedure is harder to challenge than a plot, because everyone involved can point to the rule they followed.

Medicine as it should be is not a fantasy of a different science. It is the same science with the record open, the null results published, the cheap questions funded, the harms counted, and the clinician free to follow the evidence to the patient in front of them. That version is entirely available. It is not being run.

This page states the framework's argument, not a finding of any court or regulator. Each row is testable: the sources that would prove it, or break it, belong in the evidence ledger, and the ledger is published with its statuses intact.